Reply to Panday and sturkenboom

Clinical Infectious Diseases

Volumn 49, Issue 12, 2009, Pages 1965-

  Rybak, Michael J ^a,b,c,i   Lomaestro, Ben ^d   Rotschafer, John ^e   Moellering Jr , Robert C ^f,g,h   Levine, Donald P ^b,c  

^a Anti Infective Research Laboratory   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DETROIT RECEIVING HOSPITAL   (United States)

^d ALBANY MEDICAL CENTER   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

^f Shields Warren Mallinckrodt Medical Research   (United States)

^g HARVARD MEDICAL SCHOOL   (United States)

^h BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

ⁱ WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VANCOMYCIN;

AREA UNDER THE CURVE; CONTINUOUS INFUSION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG INTERMITTENT THERAPY; DRUG SAFETY; HUMAN; LETTER; NEPHROTOXICITY; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

EID: 72049118720     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/648507     Document Type: Letter

References (8)

1. Panday PV, Sturkenboom M. Continuous infusion of vancomycin less effective and safe than intermittent infusion, based on pharmacodynamic and pharmacokinetic principles. Clin Infect Dis 2009; 49:325-327
2. Rybak MJ, Lomeastro BM, Rotschafer JC, et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, The American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009; 49:325-327
3. Wysocki M, Delateur F, Faurisson F, et al. Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective munlicenter randomized study. Antimicrob Agents Chemother 2001; 45:2460-2467 (Pubitemid 32801896)
4. James JK, Palmer SM., Levine DP, et al. Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infections. Antimicrob Agents Chemother 1996; 40:696-700.
5. Pea F, Furlanut M, Negri C, et al. Prospectively validated dosing nomograms for maximizing the pharmacodynamics of vancomycin administered by continuous infusion in critically ill patients. Antimicrob Agents Chemother 2009; 53:1863-1867
6. Ingram PR, Lye DC, Tambyah PA, et al. Risk factors for nephrotoxicity associated with continuous infusion in outpatient parenteral antibiotic therapy. J Antimicrob Chemother 2008; 62:168-171
7. El Amari EB., Vugnat A., Stern R, et al. High versus standard dose vancomycin for ostemyelitis. Scand J Infect Dis 2004; 36:712-717 (Pubitemid 39467935)
8. Lodise TP, Patel N, Lomaestro BM, et al. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis 2009; 49: 507-514